{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Métastase lymphatique : Questions médicales les plus fréquentes",
"headline": "Métastase lymphatique : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Métastase lymphatique : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-28",
"dateModified": "2025-02-22",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Métastase lymphatique"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Métastase tumorale",
"url": "https://questionsmedicales.fr/mesh/D009362",
"about": {
"@type": "MedicalCondition",
"name": "Métastase tumorale",
"code": {
"@type": "MedicalCode",
"code": "D009362",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550.727.650"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Métastase lymphatique",
"alternateName": "Lymphatic Metastasis",
"code": {
"@type": "MedicalCode",
"code": "D008207",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Yanshi Li",
"url": "https://questionsmedicales.fr/author/Yanshi%20Li",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Tao Lu",
"url": "https://questionsmedicales.fr/author/Tao%20Lu",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Guohua Hu",
"url": "https://questionsmedicales.fr/author/Guohua%20Hu",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Tianxin Lin",
"url": "https://questionsmedicales.fr/author/Tianxin%20Lin",
"affiliation": {
"@type": "Organization",
"name": "Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. Electronic address: lintx@mail.sysu.edu.cn."
}
},
{
"@type": "Person",
"name": "Changhao Chen",
"url": "https://questionsmedicales.fr/author/Changhao%20Chen",
"affiliation": {
"@type": "Organization",
"name": "Department of Urology, Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Racial and ethnic disparities in surgery for kidney cancer: a SEER analysis, 2007-2014.",
"datePublished": "2023-05-10",
"url": "https://questionsmedicales.fr/article/37165613",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/13557858.2023.2212145"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prognostic Nomogram for Gastrointestinal Stromal Tumors after Surgery Based on the SEER Database.",
"datePublished": "2022-11-14",
"url": "https://questionsmedicales.fr/article/36420093",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1155/2022/5639174"
}
},
{
"@type": "ScholarlyArticle",
"name": "Survival and analysis of prognostic factors for primary malignant cardiac tumors based on the SEER database.",
"datePublished": "2023-09-04",
"url": "https://questionsmedicales.fr/article/37665405",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00432-023-05351-4"
}
},
{
"@type": "ScholarlyArticle",
"name": "Conditional Cancer-Specific Survival for Inflammatory Breast Cancer: Analysis of SEER, 2010 to 2016.",
"datePublished": "2023-05-19",
"url": "https://questionsmedicales.fr/article/37286434",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.clbc.2023.05.005"
}
},
{
"@type": "ScholarlyArticle",
"name": "Value of thyroid cancer history in the prognosis of pancreatic cancer: a SEER population-based study.",
"datePublished": "2023-04-08",
"url": "https://questionsmedicales.fr/article/37031235",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-023-32635-z"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "États, signes et symptômes pathologiques",
"item": "https://questionsmedicales.fr/mesh/D013568"
},
{
"@type": "ListItem",
"position": 3,
"name": "Processus pathologiques",
"item": "https://questionsmedicales.fr/mesh/D010335"
},
{
"@type": "ListItem",
"position": 4,
"name": "Processus néoplasiques",
"item": "https://questionsmedicales.fr/mesh/D009385"
},
{
"@type": "ListItem",
"position": 5,
"name": "Métastase tumorale",
"item": "https://questionsmedicales.fr/mesh/D009362"
},
{
"@type": "ListItem",
"position": 6,
"name": "Métastase lymphatique",
"item": "https://questionsmedicales.fr/mesh/D008207"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Métastase lymphatique - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Métastase lymphatique",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Métastase lymphatique",
"description": "Comment diagnostiquer une métastase lymphatique ?\nQuels tests sont utilisés pour détecter des métastases ?\nQuels signes indiquent une métastase lymphatique ?\nPeut-on détecter des métastases par analyse sanguine ?\nQuel rôle joue l'imagerie dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D008207?mesh_terms=SEER+Program&page=4#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Métastase lymphatique",
"description": "Quels sont les symptômes des métastases lymphatiques ?\nLes métastases lymphatiques causent-elles des douleurs ?\nPeut-on avoir des symptômes sans métastases visibles ?\nLes symptômes varient-ils selon le type de cancer ?\nComment les symptômes évoluent-ils avec le temps ?",
"url": "https://questionsmedicales.fr/mesh/D008207?mesh_terms=SEER+Program&page=4#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Métastase lymphatique",
"description": "Peut-on prévenir les métastases lymphatiques ?\nQuels facteurs de risque augmentent les métastases ?\nL'alimentation influence-t-elle le risque de métastases ?\nLe dépistage régulier est-il important ?\nLes vaccinations peuvent-elles aider ?",
"url": "https://questionsmedicales.fr/mesh/D008207?mesh_terms=SEER+Program&page=4#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Métastase lymphatique",
"description": "Quels traitements sont disponibles pour les métastases lymphatiques ?\nLa radiothérapie est-elle efficace contre les métastases ?\nQuand la chirurgie est-elle recommandée ?\nQuels médicaments sont utilisés pour traiter les métastases ?\nLes traitements sont-ils personnalisés ?",
"url": "https://questionsmedicales.fr/mesh/D008207?mesh_terms=SEER+Program&page=4#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Métastase lymphatique",
"description": "Quelles complications peuvent survenir avec les métastases ?\nLes métastases lymphatiques affectent-elles la fonction immunitaire ?\nComment les métastases impactent-elles la qualité de vie ?\nLes métastases peuvent-elles causer des problèmes respiratoires ?\nY a-t-il un risque d'infection avec les métastases ?",
"url": "https://questionsmedicales.fr/mesh/D008207?mesh_terms=SEER+Program&page=4#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Métastase lymphatique",
"description": "Quels cancers sont plus susceptibles de métastaser par voie lymphatique ?\nLe tabagisme est-il un facteur de risque ?\nL'âge influence-t-il le risque de métastases ?\nLes antécédents familiaux jouent-ils un rôle ?\nL'obésité est-elle un facteur de risque pour les métastases ?",
"url": "https://questionsmedicales.fr/mesh/D008207?mesh_terms=SEER+Program&page=4#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une métastase lymphatique ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic se fait par imagerie (IRM, TDM) et biopsie des ganglions lymphatiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour détecter des métastases ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent l'échographie, la tomographie et la scintigraphie lymphatique."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une métastase lymphatique ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un gonflement des ganglions lymphatiques et des douleurs localisées peuvent indiquer des métastases."
}
},
{
"@type": "Question",
"name": "Peut-on détecter des métastases par analyse sanguine ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les analyses sanguines peuvent révéler des marqueurs tumoraux, mais ne suffisent pas pour le diagnostic."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'imagerie dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie permet de visualiser l'étendue des métastases et d'évaluer les ganglions lymphatiques."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes des métastases lymphatiques ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des ganglions enflés, douleur, fatigue et perte de poids."
}
},
{
"@type": "Question",
"name": "Les métastases lymphatiques causent-elles des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent provoquer des douleurs localisées au niveau des ganglions touchés."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes sans métastases visibles ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains patients peuvent présenter des symptômes sans métastases détectables par imagerie."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type de cancer ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction du type de cancer primaire et de sa localisation."
}
},
{
"@type": "Question",
"name": "Comment les symptômes évoluent-ils avec le temps ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent s'aggraver avec la progression de la maladie et l'extension des métastases."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les métastases lymphatiques ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par un dépistage précoce et un traitement efficace des cancers primaires."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque augmentent les métastases ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux, le tabagisme et l'obésité sont des facteurs de risque connus."
}
},
{
"@type": "Question",
"name": "L'alimentation influence-t-elle le risque de métastases ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation saine peut réduire le risque de cancer et donc de métastases lymphatiques."
}
},
{
"@type": "Question",
"name": "Le dépistage régulier est-il important ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le dépistage régulier permet de détecter les cancers à un stade précoce, réduisant le risque de métastases."
}
},
{
"@type": "Question",
"name": "Les vaccinations peuvent-elles aider ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines vaccinations, comme celles contre le HPV, peuvent réduire le risque de cancers associés."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les métastases lymphatiques ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la chirurgie, la radiothérapie et la chimiothérapie ciblée."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle efficace contre les métastases ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la radiothérapie peut réduire la taille des métastases et soulager les symptômes."
}
},
{
"@type": "Question",
"name": "Quand la chirurgie est-elle recommandée ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chirurgie est recommandée si les métastases sont localisées et accessibles sans risque majeur."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont utilisés pour traiter les métastases ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme les inhibiteurs de tyrosine kinase et l'immunothérapie sont utilisés."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements sont souvent adaptés en fonction du type de cancer et de l'état du patient."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les métastases ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'obstruction lymphatique, la douleur chronique et l'infection."
}
},
{
"@type": "Question",
"name": "Les métastases lymphatiques affectent-elles la fonction immunitaire ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent compromettre la fonction immunitaire en affectant les ganglions lymphatiques."
}
},
{
"@type": "Question",
"name": "Comment les métastases impactent-elles la qualité de vie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent entraîner des douleurs, une fatigue accrue et des limitations fonctionnelles."
}
},
{
"@type": "Question",
"name": "Les métastases peuvent-elles causer des problèmes respiratoires ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, si elles se propagent aux ganglions lymphatiques thoraciques, cela peut affecter la respiration."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque d'infection avec les métastases ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les métastases peuvent augmenter le risque d'infections en compromettant le système lymphatique."
}
},
{
"@type": "Question",
"name": "Quels cancers sont plus susceptibles de métastaser par voie lymphatique ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les cancers du sein, du poumon et de la peau sont souvent associés à des métastases lymphatiques."
}
},
{
"@type": "Question",
"name": "Le tabagisme est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme augmente le risque de plusieurs cancers, favorisant les métastases."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de métastases ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de métastases augmente avec l'âge en raison de la diminution de l'immunité."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de cancer augmentent le risque de développer des métastases."
}
},
{
"@type": "Question",
"name": "L'obésité est-elle un facteur de risque pour les métastases ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'obésité est associée à un risque accru de plusieurs cancers et de métastases."
}
}
]
}
]
}
Compared with White patients, Black and American Indian/Alaskan Native (AI/AN) patients experience higher rates of kidney cancer incidence, and Black, AI/AN, and Hispanic patients face later stages of...
96,745 patients ages 45-84 with kidney cancer were identified in the Surveillance, Epidemiology, and End Results (SEER) program between 2007 and 2014. Logistic regression models were used to examine t...
Relative to White patients, Black and AI/AN patients had lower odds of undergoing any surgical procedure (OR = 0.76; 95% CI: 0.72-0.81;...
Compared with White patients, Black patients were less likely to receive potentially life-saving surgery, and both Black and AI/AN patients were more likely to refuse recommended surgery....
We aimed to determine prognostic factors and develop an effective and practical nomogram for predicting cancer-specific survival in gastrointestinal stromal tumor (GIST) patients. Postoperative data w...
The purpose of this study was to use the Surveillance, Epidemiology, and End Results (SEER) database to evaluate the survival rate of primary malignant cardiac tumors (PMCTs), assess the risk factors ...
SEER 22 registries were used to calculate the number of cases PMCT. Data on age, sex, race, marital status, tumor size, the American Joint Committee on Cancer (AJCC) stage, lymph node involvement, met...
In recent years, the average annual number of PMCT cases was 20.56 ± 7.12, significantly higher than the average before 2004 (P = 0.015; 95% CI 1.14-8.98). The 1-, 3-, and 5-year survival rates were 4...
In recent years, the annual number of patients with PMCT has increased significantly. Due to developments in chemotherapy, we should re-evaluate the traditional tumor staging and prognostic risk indic...
Conditional survival takes into account the time that has elapsed since diagnosis and may have additional informative value. Compared with the static traditional survival evaluation method, conditiona...
Of 3333 patients diagnosed with inflammatory breast cancer between 2010 and 2016 were extracted from the Surveillance, Epidemiology, and End Results database. The trend of the hazard rate over time wa...
Of 3333 patients, the cancer-specific survival (CSS) rate decreased from 57% in the 4th year to 49% in the 6th year, while the comparable 3-year CS (CS3) rate improved from 65% in the first year to 76...
High-risk patients had a significantly improved cancer-specific survival prognosis after surviving for 1 or more years after diagnosis with inflammatory breast cancer. The probability of reaching 5-ye...
Thyroid cancer patients have a good prognosis, and their long survival increases the likelihood of developing a second primary tumor. Meanwhile, pancreatic cancer (PC) has a poor prognosis and therape...
The study aimed to construct prognostic models for OS and CSS in patients with T1N0M0 glottic SCC. In addition, we used PSM to re-assess the effect of surgery alone and radiation alone....
The Surveillance, Epidemiology, and End Results database was searched for patients with confirmed T1N0M0 glottic SCC. Patients with complete data were randomly divided into the training and the valida...
A total 1827 patients met the inclusion criteria. Survival analysis indicated that the patients who underwent the primary site surgery had a better OS (P = 0.002) and CSS (P = 0.008), compared with no...
Nomogram models were developed to predict OS and CSS in patients with T1N0M0 glottic SCC. Primary site surgery could definitely increase OS and CSS, while radiation could significantly increase CSS. U...
Three nomograms for predicting the outcomes of early- and late-onset colon cancer (COCA) among patients not stratified by age were constructed using data in the Epidemiology and End Results (SEER) dat...
Clinical data of 6107 patients with COCA were obtained from the SEER database. The patients were randomly divided into training and validation cohorts in a ratio of 7:3. Univariate and multivariate CO...
Tumor primary site, ethnicity, and serum carcinoembryonic antigen (CEA) level significantly impacted the prognosis of colon cancer. Race, brain metastasis, and CEA were independent factors for predict...
Three nomograms for patients not stratified by age, early-onset colon cancer, and late-onset colon cancer were constructed. The accuracies of the nomograms were good and were all superior to the conve...
The relationship between marital status and overall survival (OS) in adult patients with craniopharyngioma has not been explored in depth. We aimed to elucidate the impact of marital status on the pro...
We extracted 1539 patients diagnosed with craniopharyngioma between 2000 and 2019 from the Surveillance, Epidemiology, and End Results database and divided patients into 4 marital subgroups: married, ...
There were 1539 eligible patients: 863 (56.1%) were married, 466 (30.3%) were single, 135 (8.8%) were divorced/separated, and 75 (4.9%) were widowed. Widowed patients had the worst mean OS, 5-year OS ...
Marital status is an independent prognostic factor predicting OS for middle-aged patients with craniopharyngioma. Providing additional social and psychological support for single and divorced/separate...
This study aims to analyze the clinicopathological characteristics and survival outcomes of cutaneous soft tissue sarcomas (CSTS) in children. We selected pediatric cases of CSTS diagnosed between 200...
This study aims to develop and validate a nomogram for predicting overall survival (OS) in Asian patients with Esophageal Cancer (EC). Data from Asian EC patients were collected from the Surveillance,...